Please assess the completion status of the following clinical trial:

Trial Title: PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females, aged ≥ 18 years at time of consent.~* Have a diagnosis of Psoriatic Arthritis (PsA, by any criteria) of ≥ 6 months duration.~* Meet the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria for PsA at time of screening.~* Must have been inadequately treated by disease-modifying antirheumatic drugs (DMARDs)~* May not have axial involvement alone~* Concurrent Tx allowed with methotrexate, leflunomide, or sulfasalazine~* Have ≥ 3 swollen AND ≥ 3 tender joints.~* Males \& Females must use contraception~* Stable dose of NSAIDs, narcotics and low dose oral corticosteroids allowed.~* Have at least one ≥2 cm psoriasis lesion~Exclusion Criteria:~* Pregnant or breast feeding.~* History of allergy to any component of the investigational product Hepatitis B surface antigen and/or Hepatitis C antibody positive at screening.~* Therapeutic failure on \> 3 agents for PsA or \> 1 biologic tumor necrosis factor (TNF) blocker

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apremilast 20 mg (Type: EXPERIMENTAL): 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
- Apremilast 30 mg (Type: EXPERIMENTAL): 30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
- Placebo + 20 mg Apremilast (Type: PLACEBO_COMPARATOR): Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
- Placebo + 30 mg Apremilast (Type: PLACEBO_COMPARATOR): Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.

Based on this trial design, predict the completion outcome and termination type (if applicable).